查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999192

细胞和基因治疗製造服务市场：2026-2032年全球市场预测（按服务类型、技术类型、治疗领域、应用和最终用户划分）

Cell & Gene Therapy Manufacturing Services Market by Service Type, Technology Type, Therapeutic Area, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞和基因治疗製造服务市场价值将达到 230.6 亿美元，到 2026 年将成长至 266.1 亿美元，到 2032 年将达到 669.2 亿美元，复合年增长率为 16.43%。

主要市场统计数据
基准年 2025 230.6亿美元
预计年份：2026年 266.1亿美元
预测年份：2032年 669.2亿美元
复合年增长率 (%) 16.43%

权威的介绍说明了为什么细胞和基因治疗製造服务对于临床成功和商业化策略至关重要。

细胞和基因治疗生产服务产业已从零散的先导计画发展成为先进疗法开发中至关重要的策略要素。如今，卓越的生产能力不仅决定临床应用的速度，也决定复杂生技药品商业化的可行性。本执行摘要概述了正在重塑企业制定生产策略和选择外部合作伙伴方式的营运、技术、监管和商业性趋势。

技术进步、营运数位化和监管期望共同作用，迫使整个细胞和基因治疗製造服务进行策略重组。

该产业正经历一场变革性的变革，这场变革从根本上改变了治疗方法的研发和生产方式。基因编辑技术的进步、病毒和非病毒载体的日益普及以及先进分析工具的出现，提高了人们对疗法可重复性和疗效的技术要求。同时，基于平台的製程开发和模组化设施设计正在兴起，这不仅能加快生产规模，也能确保产品品质和符合监管要求。

了解 2025 年美国关税措施对全球供应链和製造业韧性的多层次营运和策略影响。

2025年推出的最新关税措施进一步加剧了本已错综复杂的细胞和基因治疗生产全球供应链的复杂性。进口关税及相关贸易措施提高了许多进口原料、特殊试剂和生产设备的相对成本和前置作业时间。因此，各机构正在重新审视其供应商组合和筹资策略，以减轻跨境价格波动的影响。

详细的細項分析揭示了服务类型、技术平台、治疗领域、应用和最终用户需求如何塑造提供者的定位。

细分市场分析揭示了不同服务类型、技术平台、治疗适应症、应用场景和最终用户类别所面临的优先挑战各不相同。每种服务类型——分析和品管服务、细胞库服务、咨询服务、灌装和包装服务、GMP生产服务、製程开发服务、法规支援服务、供应链物流服务、技术转移服务和载体生产服务——都面临独特的能力和产能要求。能够提供将载体生产与强大的分析和法规支援相结合的整合服务方案的供应商，对寻求透过单一供应商降低风险的开发商更具吸引力。另一方面，专注于有限服务范围的高度专业化供应商，可以透过提供卓越的技术深度和客製化解决方案来占据市场领先地位。

区域比较分析，阐述美洲、欧洲、中东和非洲以及亚太地区如何影响战略製造和伙伴关係决策。

区域趋势显着影响企业在生产能力投资地点、合作伙伴选择以及专业能力配置方面的决策。在美洲，由契约製造、大学衍生企业和创业投资支持的研发公司组成的密集生态系统，为转化研究提供了快速通道，同时监管机构也为先进治疗方法提供了日益成熟的指导框架。鑑于大规模的患者群体和接近性资本市场的地理优势，这种环境有利于垂直整合策略和载体生产能力的投资。

企业策略行动和竞争动态决定了哪个供应商赢得订单以及如何建立伙伴关係。

企业行为揭示了这样一个市场现实：策略差异化源自于广泛的能力、技术专长和伙伴关係模式。领先的服务供应商透过整合载体生产、製程开发和分析平台的投资，提供从早期开发到商业化的一体化流程。这些能力吸引了寻求可预测进度的赞助商，因为它们减少了技术交接环节，并降低了专案风险。同时，专注于高度复杂细分领域（例如AAV生产、非病毒递送平台或高级分析）的专业公司，凭藉其可重复的技术性能和深厚的监管专业知识，赢得了高价值合约。

为产业领导者提供实际有效的建议，以加强供应链、加速技术转移并确保製造业的未来发展。

领导者应优先采取一系列切实可行的措施，以降低风险、加速研发进度并保障利润率。首先，应实现关键试剂和设备的来源多元化，核实二级供应商的合格，并建立长期合约保障机制，以降低关税和供应链中断的影响。同时，应投资建立强大的分析能力和标准化检测方法，以缩短技术转移过程中的资格确认週期，并加快监管申报流程。

一种透明的混合研究途径，结合了与专家的初步访谈、能力映射和情境检验，以支持策略洞察。

支持这些见解的研究采用了一种混合方法，结合了专家访谈、技术评估和文件分析。主要资讯来源包括对申办方和提供方机构生产部门的高阶主管、品质经理和法规专家进行的结构化访谈，从而深入观点营运限制和策略重点。这些定性见解与监管指南、同行评审文献以及公开资讯的技术审查进行了交叉比对，以检验有关技术趋势和能力的论点。

简明扼要地总结了为何生产能力、监管合规性和供应链韧性是决定先进治疗方法开发成功与否的关键因素。

细胞和基因治疗生产服务领域正处于转折点，技术进步、不断变化的监管环境以及地缘政治因素共同塑造战略选择。建构模组化、数据主导流程并建立多元化供应商网路的供应商和申办方，更有可能克服关税阻力和区域营运的复杂性。儘早与监管机构沟通并建立可验证的品管体系，仍然是成功进行技术转移和商业化的必要前提。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：细胞与基因治疗製造服务市场：依服务类型划分

  • 分析和品管服务
  • 手机银行服务
  • 咨询服务
  • 灌装和精加工服务
  • GMP生产服务
  • 流程开发服务
  • 监理合规服务
  • 供应链物流服务
  • 技术转移服务
  • 向量製作服务

第九章：细胞与基因治疗製造服务市场：依技术类型划分

  • 基因编辑
    • CRISPR/Cas9
    • 转录活化因子样效应核酸酶
    • 锌指核酸酶
  • 向量
    • 非病毒载体
      • 阳离子脂质
      • 基于几丁聚醣的载体
      • 树状聚合物
      • 无机奈米粒子
      • 脂质奈米颗粒
      • 裸露的DNA/RNA
      • 基于胜肽的载体
      • 聚合物载体
    • 病毒载体
      • 腺结合病毒（AAV）载体
      • 腺病毒载体
      • 单纯疱疹病毒（HSV）载体
      • 逆转录病毒载体

第十章 细胞与基因治疗製造服务市场：依治疗领域划分

  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 单基因疾病
    • 囊肿纤维化
    • 血友病
    • 镰状细胞贫血症
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌

第十一章：细胞与基因治疗製造服务市场：依应用领域划分

  • 临床生产
  • 商业製造

第十二章 细胞与基因治疗製造服务市场：依最终用户划分

  • 合约研究机构
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构和学术机构

第十三章：细胞与基因治疗製造服务市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：细胞与基因治疗製造服务市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 细胞与基因疗法製造服务市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞与基因治疗製造服务市场

第十七章：中国细胞与基因治疗製造服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced BioScience Laboratories, Inc. （Institut Merieux）
  • AGC Biologics
  • AmplifyBio
  • Bio-Techne Corporation
  • CH Boehringer Sohn AG & Co. KG
  • Catalent, Inc.
  • Cell Therapies Pty Ltd.
  • Cell-Easy
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • eXmoor Pharma Concepts Limited
  • FUJIFILM Diosynth BIoTechnologies
  • Genezen Laboratories, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi BIoTec BV & Co. KG
  • Minaris Regenerative Medicine GmbH by Resonac Corporation
  • Nikon Corporation
  • Novartis AG
  • Oxford Biomedica PLC
  • ProPharma Group Holdings, LLC
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • SGS SA
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uBriGene Biosciences Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-BB6269D1414B

The Cell & Gene Therapy Manufacturing Services Market was valued at USD 23.06 billion in 2025 and is projected to grow to USD 26.61 billion in 2026, with a CAGR of 16.43%, reaching USD 66.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 23.06 billion
Estimated Year [2026] USD 26.61 billion
Forecast Year [2032] USD 66.92 billion
CAGR (%) 16.43%

An authoritative introduction framing why manufacturing services for cell and gene therapies are now pivotal to clinical success and commercialization strategies

The cell and gene therapy manufacturing services landscape has matured from fragmented pilot projects to a strategically critical component of advanced therapeutics development. Manufacturing excellence now determines not only the speed of clinical translation but also the viability of commercialization for complex biologics. This executive summary synthesizes operational, technological, regulatory, and commercial dynamics that are reshaping how organizations design manufacturing strategies and select external partners.

Across the value chain, precision in analytical methods, reliability in supply chains, and robustness in process development have become decisive competitive differentiators. Manufacturers and service providers must simultaneously manage biologic complexity, regulatory stringency, and an increasingly globalized supplier base. Consequently, senior leaders are prioritizing investments in platform technologies, quality systems, and integrated services that reduce technical risk while accelerating time to clinic.

The following sections examine structural shifts, the implications of recent trade policy interventions, segmentation-specific dynamics, regional contrasts, corporate strategic behaviors, and pragmatic recommendations for industry leaders. Each element is framed to support clear decision-making pathways for organizations evaluating manufacturing partnerships, capacity investments, or capability development initiatives.

How converging technical advances, operational digitization, and regulatory expectations are forcing strategic reinvention across cell and gene therapy manufacturing services

The industry is undergoing transformative shifts that are altering the fundamentals of how therapies are developed and manufactured. Advances in gene editing, expanding use cases for viral and non-viral vectors, and refined analytical tools are raising technical expectations for reproducibility and potency. In tandem, a move toward platform-based process development and modular facility designs is enabling faster scale-up while preserving product quality and regulatory compliance.

Operationally, digitization and automation are reducing variability and labor dependence in critical workflows. Machine learning and process analytics are increasingly applied to in-process controls and batch release decisions, improving lot consistency and accelerating release timelines. At the same time, decentralized and hybrid manufacturing models are gaining traction, driven by the need for geographic proximity to patients and by logistical imperatives for temperature-sensitive material handling.

Regulatory engagement has also evolved; regulators are placing greater emphasis on lifecycle quality management, comparability, and long-term safety monitoring. This has prompted closer collaboration between developers, contract manufacturers, and regulators earlier in development. Finally, strategic capital is flowing into specialized contract development and manufacturing organizations that can offer integrated services across vector production, process development, and GMP manufacturing, underscoring a market-wide shift toward end-to-end propositions that de-risk development programs.

Understanding the layered operational and strategic consequences of the 2025 United States tariff measures on global supply chains and manufacturing resilience

Recent tariff actions introduced in 2025 have created a complex overlay on an already intricate global supply chain for cell and gene therapy manufacturing. Import duties and related trade measures have increased the relative cost and lead time of many imported raw materials, specialized reagents, and manufacturing equipment. As a result, organizations are reassessing supplier portfolios and procurement strategies to mitigate exposure to cross-border pricing volatility.

In response, many developers and service providers have accelerated localization of critical inputs and invested in qualifying domestic suppliers to secure continuity of supply. These efforts often require parallel investments in quality assurance and regulatory alignment to ensure substitutes meet stringent GMP expectations. Consequently, procurement teams are devoting more resources to supplier qualification, audit readiness, and long-term contracting mechanisms that lock in quality and delivery terms.

Contract manufacturers and technology vendors are adjusting commercial models to absorb some tariff-related friction through alternative sourcing, forward purchasing, and contractual pricing clauses. Moreover, trade measures have intensified the strategic rationale for regional manufacturing footprints, where proximity reduces tariff exposure, shortens distribution pathways, and enhances compliance with local regulatory frameworks. Taken together, the cumulative impact of tariffs is not only financial but also structural, prompting organizations to rethink how manufacturing networks should be organized for resilience and regulatory congruence.

Deep segmentation insights that reveal how distinct service types, technology platforms, therapeutic focuses, applications, and end-user needs shape provider positioning

Segmentation analysis reveals differentiated imperatives across service types, technology platforms, therapeutic indications, application contexts, and end-user categories. Service types such as Analytical & Quality Control Services, Cell Banking Services, Consulting Services, Fill & Finish Services, GMP Manufacturing Services, Process Development Services, Regulatory Support Services, Supply Chain & Logistics Services, Technology Transfer Services, and Vector Production Services each face unique capability and capacity demands. Providers offering integrated suites that combine vector production with robust analytics and regulatory support achieve greater appeal to developers seeking single-vendor risk reduction. Conversely, highly specialized providers that concentrate on a narrow set of services can secure premium positioning by delivering superior technical depth and bespoke solutions.

Technology type segmentation differentiates organizations working in Gene Editing and Vectors. Within Gene Editing, approaches such as CRISPR/Cas9, Transcription Activator-Like Effector Nucleases, and Zinc Finger Nucleases require distinct process development pathways and regulatory dossiers. Vector technologies split into Non-Viral and Viral Vectors; Non-Viral Vectors encompass cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, each with divergent formulation and delivery considerations. Viral Vectors include adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, and these necessitate specialized containment, production platforms, and potency assays. Firms that can demonstrate cross-platform expertise or rapid transferability between these technology types are better positioned to capture emerging program demand.

Therapeutic area segmentation distinguishes development pathways across cardiovascular diseases, infectious diseases, monogenic disorders, and oncology. Within cardiovascular diseases, programs focused on coronary artery disease and heart failure require distinct safety and delivery strategies compared with infectious disease programs targeting hepatitis B or HIV. Monogenic disorder efforts such as cystic fibrosis, hemophilia, and sickle cell anemia emphasize curative intent and long-term follow-up, imposing rigorous controls on vector biodistribution and persistence. Oncology programs, split between hematological malignancies and solid tumors, demand divergent manufacturing scales and release criteria due to differing dosing paradigms and cell types.

Application-based segmentation differentiates clinical manufacturing from commercial manufacturing. Clinical manufacturing emphasizes flexibility, rapid changeover, and small-batch reproducibility, while commercial manufacturing demands robust scale, cost efficiencies, and validated high-throughput analytics. End-user segmentation highlights the varied buying behaviors and capability expectations of contract research organizations, hospitals & clinics, pharmaceutical & biotech companies, and research institutes & academic institutions. CROs prioritize rapid turnaround and regulatory alignment, hospitals and clinics seek localized solutions for patient-centric delivery, pharmaceutical and biotech companies emphasize integrated development-to-commercial pathways, and research institutes focus on platform access and technology transfer support. Understanding these intersecting segmentation layers enables providers and sponsors to tailor propositions that align technical strengths with buyer priorities and therapeutic requirements.

Comparative regional intelligence explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape strategic manufacturing and partnership decisions

Regional dynamics materially influence where organizations choose to invest in capacity, partner with contractors, and locate specialized capabilities. In the Americas, a dense ecosystem of contract manufacturers, academic spinouts, and venture-backed developers supports rapid translational pathways, while regulatory agencies are offering increasingly mature guidance frameworks for advanced therapies. This environment encourages vertically integrated strategies and investments in vector production capacity, given the proximity to large patient populations and capital markets.

Europe, the Middle East & Africa present a heterogeneous landscape, with centers of excellence clustered in countries that combine favorable regulatory clarity with advanced biomanufacturing infrastructure. Cross-border collaborations within Europe facilitate access to skilled labor and analytic expertise, yet fragmented reimbursement and localized regulatory nuances require tailored market entry strategies. In parts of the Middle East and Africa, strategic partnerships and knowledge transfer initiatives are emerging, often driven by government-led capacity-building programs.

Asia-Pacific stands out for rapid expansion of manufacturing capacity, significant public and private investment in biotech ecosystems, and a growing cadre of specialized manufacturing service providers. Regulatory pathways in several jurisdictions are evolving to accommodate advanced therapies, and regional supply chain advantages-particularly in reagents and equipment manufacturing-are prompting multinational developers to consider Asia-Pacific-based production as part of global strategies. Each region's regulatory posture, talent availability, and supply chain topology should inform decisions about where to site facilities, which services to insource, and how to structure commercial partnerships for long-term resilience.

Strategic company behaviors and competitive dynamics that determine which providers are winning mandates and how partnerships are being structured

Corporate behaviors reveal a market in which strategic differentiation emerges from capability breadth, technological specialization, and partnership models. Leading service providers are combining investments in vector production, process development, and analytical platforms to offer integrated pathways from early development through commercialization. These capabilities reduce technical handoffs and lower program risk, attracting sponsors seeking predictable timelines. At the same time, specialized firms that focus on high-complexity niches-such as AAV manufacturing, non-viral delivery platforms, or advanced analytics-are capturing premium mandates by demonstrating reproducible technical performance and deep regulatory know-how.

Strategic alliances and M&A activity are common mechanisms for acquiring missing capabilities rapidly, particularly when organizations aim to move from service provision to platform ownership. Outsourcing models continue to diversify; some pharmaceutical and biotech companies pursue co-investment in dedicated facilities to secure capacity, while others prefer flexible, fee-for-service engagements. Quality systems, regulatory track records, and demonstrated technology transfer experience are decisive contracting criteria. Additionally, firms that adopt digital quality management systems, robust batch record traceability, and advanced environmental monitoring differentiate themselves through lower deviation rates and faster regulatory inspections.

The competitive landscape also values transparent risk-sharing agreements, milestone-based pricing, and hybrid commercial structures that align incentives between sponsors and manufacturers. Finally, a growing subset of companies is investing in sustainable manufacturing practices and circular supply chain initiatives, which signal long-term operational discipline and can influence procurement decisions among environmentally conscious sponsors.

Practical high-impact recommendations for industry leaders to fortify supply chains, accelerate technology transfer, and future-proof manufacturing operations

Leaders should prioritize a set of actionable measures that reduce risk, accelerate development timelines, and protect margins. First, diversify sourcing for critical reagents and equipment while qualifying secondary suppliers and establishing long-term contractual safeguards to mitigate tariff and supply chain disruptions. Parallel to this, invest in robust analytical capability and standardized assays to shorten qualification timelines during technology transfer and to support faster regulatory submissions.

Second, adopt modular and platform-focused process architectures that enable seamless scale transitions from clinical to commercial contexts. This includes standardizing unit operations, harmonizing documentation, and embedding digital process controls to lower variability. Third, pursue strategic partnerships that combine technical depth with commercial reach; co-locating vector production with downstream fill-and-finish or analytics can materially reduce handoff risks and improve overall program timelines.

Fourth, engage proactively with regulators earlier in development to align on comparability strategies, potency assays, and long-term safety monitoring. Fifth, enhance workforce competency through targeted upskilling programs focused on GMP best practices, advanced analytics, and equipment automation. Sixth, consider regional footprint decisions through the lens of tariff exposure, talent availability, and proximity to clinical sites. Finally, incorporate sustainability metrics into facility planning and supplier selection to reduce long-term operational risk and to meet emerging stakeholder expectations.

A transparent hybrid research approach blending primary expert interviews, capability mapping, and scenario validation to underpin strategic insights

The research underpinning these insights relied on a hybrid methodology that combined expert interviews, technology assessments, and documentary analysis. Primary inputs included structured interviews with senior manufacturing leaders, quality heads, and regulatory experts across sponsor and provider organizations, which provided granular perspectives on operational constraints and strategic priorities. These qualitative insights were triangulated with technical reviews of regulatory guidance, peer-reviewed literature, and public disclosures to validate technology trends and capability claims.

A detailed capability-mapping exercise assessed service providers across vector production, process development, GMP manufacturing, analytics, and regulatory support. Technology readiness and transferability were evaluated through criteria such as platform maturity, historical comparability studies, and demonstrated commercial-scale runs. Supply chain resilience assessments considered supplier concentration, geographic exposure, and lead-time sensitivities.

Data validation included cross-referencing interview findings with third-party technical reports and observed regulatory outcomes. Scenario-based analysis explored alternative configurations for manufacturing networks and supplier strategies under varying trade and capacity conditions. The methodology emphasized transparency and reproducibility: documentation of interview protocols, inclusion criteria for capability assessments, and the rationale for scenario parameters are available to buyers as part of the research package.

A concise concluding perspective on why manufacturing capability, regulatory alignment, and supply chain resilience will determine success in advanced therapy development

The cell and gene therapy manufacturing services sector stands at an inflection point where technical progress, regulatory evolution, and geopolitical influences collectively shape strategic choices. Providers and sponsors that build modular, analytics-driven processes and secure diversified supplier networks will be better equipped to navigate tariff-driven headwinds and regional operational complexities. Early regulatory engagement and demonstrable quality systems remain non-negotiable prerequisites for successful technology transfer and commercialization.

Organizations must balance the competing imperatives of scale, flexibility, and risk reduction. Those that opt for integrated platform strategies or targeted partnerships can shorten timelines and lower program attrition, while specialists that concentrate on niche capabilities will continue to be essential for addressing high-complexity technical challenges. Ultimately, deliberate investments in process standardization, workforce capability, and regional resilience will determine competitive positioning in a market where manufacturing excellence increasingly equals therapeutic success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Manufacturing Services Market, by Service Type

  • 8.1. Analytical & Quality Control Services
  • 8.2. Cell Banking Services
  • 8.3. Consulting Services
  • 8.4. Fill & Finish Services
  • 8.5. GMP Manufacturing Services
  • 8.6. Process Development Services
  • 8.7. Regulatory Support Services
  • 8.8. Supply Chain & Logistics Services
  • 8.9. Technology Transfer Services
  • 8.10. Vector Production Services

9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type

  • 9.1. Gene Editing
    • 9.1.1. CRISPR/Cas9
    • 9.1.2. Transcription Activator-Like Effector Nucleases
    • 9.1.3. Zinc Finger Nucleases
  • 9.2. Vectors
    • 9.2.1. Non-Viral Vectors
      • 9.2.1.1. Cationic Lipids
      • 9.2.1.2. Chitosan-Based Vectors
      • 9.2.1.3. Dendrimers
      • 9.2.1.4. Inorganic Nanoparticles
      • 9.2.1.5. Liposomes
      • 9.2.1.6. Naked DNA/RNA
      • 9.2.1.7. Peptide-Based Vectors
      • 9.2.1.8. Polymeric Vectors
    • 9.2.2. Viral Vectors
      • 9.2.2.1. Adeno-Associated Virus (AAV) Vectors
      • 9.2.2.2. Adenovirus Vectors
      • 9.2.2.3. Herpes Simplex Virus (HSV) Vectors
      • 9.2.2.4. Retrovirus Vectors

10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
    • 10.1.1. Coronary Artery Disease
    • 10.1.2. Heart Failure
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. HIV
  • 10.3. Monogenic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Hemophilia
    • 10.3.3. Sickle Cell Anemia
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Solid Tumors

11. Cell & Gene Therapy Manufacturing Services Market, by Application

  • 11.1. Clinical Manufacturing
  • 11.2. Commercial Manufacturing

12. Cell & Gene Therapy Manufacturing Services Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes & Academic Institutions

13. Cell & Gene Therapy Manufacturing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Manufacturing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Manufacturing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Manufacturing Services Market

17. China Cell & Gene Therapy Manufacturing Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced BioScience Laboratories, Inc. by Institut Merieux
  • 18.6. AGC Biologics
  • 18.7. AmplifyBio
  • 18.8. Bio-Techne Corporation
  • 18.9. C.H. Boehringer Sohn AG & Co. KG
  • 18.10. Catalent, Inc.
  • 18.11. Cell Therapies Pty Ltd.
  • 18.12. Cell-Easy
  • 18.13. Charles River Laboratories International, Inc.
  • 18.14. Danaher Corporation
  • 18.15. eXmoor Pharma Concepts Limited
  • 18.16. FUJIFILM Diosynth Biotechnologies
  • 18.17. Genezen Laboratories, Inc.
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. Lonza Group AG
  • 18.20. Merck KGaA
  • 18.21. Miltenyi Biotec B.V. & Co. KG
  • 18.22. Minaris Regenerative Medicine GmbH by Resonac Corporation
  • 18.23. Nikon Corporation
  • 18.24. Novartis AG
  • 18.25. Oxford Biomedica PLC
  • 18.26. ProPharma Group Holdings, LLC
  • 18.27. Recipharm AB
  • 18.28. Samsung Biologics Co., Ltd.
  • 18.29. SGS S.A.
  • 18.30. STEMCELL Technologies Inc.
  • 18.31. Takara Bio Inc.
  • 18.32. Thermo Fisher Scientific Inc.
  • 18.33. uBriGene Biosciences Inc.
  • 18.34. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CELL BANKING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY FILL & FINISH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GMP MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGULATORY SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUPPLY CHAIN & LOGISTICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TRANSFER SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTOR PRODUCTION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CRISPR/CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CATIONIC LIPIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CHITOSAN-BASED VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INORGANIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PEPTIDE-BASED VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY POLYMERIC VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VECTORS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA CELL & GENE THERAPY MANUFACT